Effect of erythropoietin on COVID-19

INTERVENTION: Intervention 1: Intervention group: Group A.: The standard drug treatment is based on the treatment protocols of the National Committee of COVID‐19 and erythropoietin recombinant (EPREX Manufactured by Johnson and Johnson Pharmaceutical Company) 300 units / Kg or 4000IU as subcutaneous injection three times a day for 5 days and simultaneously Enoxaparin 1mg / kg SQ daily is also taken to prevent thrombosis. Patients' blood pressure, along with other vital signs, is checked regularly and at regular intervals. Standard drug treatment according to the treatment protocols of the National Committee for COVID‐19 includes Hydroxychloroquine / Chloroquine Phosphate: Hydroxychloroquine sulfate tablets 200 mg or chloroquine phosphate tablets 250 mg (equivalent to 150 mg base dose) 2 tablets every 12 hours on the first day and then one tablet every 12 hours for at least 7 days and up to 14 days. One of the following medications at the discretion and diagnosis of the treating physician: kaletra tablets (Lopinavir / Ritonavir) 50/200 mg every 12 hours 2 pieces after meals for at least 7 days and a maximum of 14 days. Atazanavir / Ritonavir tablets (300mg/100mg), One tablet daily with food or Atazanavir 400 mg daily for at least 7 days, and up to 14 days. Intervention 2: Control group: Group B: The standard drug treatment is based on the treatment protocols of the National Committee for COVID‐19 and the placebo(distilled water) is given as a subcutaneous injection three times a day for 5 days. Standard drug treatment according to the treatment protocols of the National Committee for COVID‐19 includes Hydroxychloroquine / Chloroquine Phosphate: Hydroxychloroquine sulfate tablets 200 mg or chloroquine phosphate tablets 250 mg (equivalent to 150 mg base dose) 2 tablets ever CONDITION: Laboratory confirmed COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: CRP level's. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pathobiology laboratory. Endogenous erythropoietin level's. Timepoint: Beginning of study (before intervention). Method of measurement: Pathobiology laboratory. LDH level's. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pathobiology laboratory. Lung infiltration status. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Chest X‐ray. Lymphocyte count. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pathobiology laboratory. Oxygen saturation state and arterial oxygen partial pressure ratio. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pulse Oximeter. Patients' blood pressure. Timepoint: At the beginning of the study (before the intervention), during the intervention (5‐day erythropoietin administration). Method of measurement: Sphygmomanometer. Respiratory rate. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pulse Oximeter. SECONDARY OUTCOME: Patients' blood hemoglobin levels. Timepoint: Start of study (before the intervention), day 5 after the intervention and 2 to 4 weeks after the intervention. Method of measurement: Pathobiology laboratory. INCLUSION CRITERIA: All definitively positive COVID‐19 patients with Hb=9. Having at least one of the severe symptoms of COVID‐19, including tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 =93 saturation, the partial pressure ratio of arterial oxygen <300), Lung infiltration (> 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100